Medtronic's Q2 Results Fuel Growth Hopes, But Analysts Remain Skeptical
AI Summary1 min read
TL;DR
Medtronic's Q2 revenue beat estimates and guidance was raised, driven by Cardiovascular and Diabetes units. However, margins contracted and analysts remain skeptical about stock optimism.
Tags
Medtronic
Medtronic reported Q2 revenue of $8.961 billion, beating consensus estimates, and raised its full-year organic revenue growth guidance to 5.5%. The company's strong performance was driven by the Cardiovascular and Diabetes businesses, but operating margins contracted and missed consensus estimates. Analysts say the growth story is improving, but the stock already reflects optimism around Medtronic's pipeline.
